Episode
259: How Peptides are Innovating Longevity Planning
- Podcast
- Innovation Storytellers
- Published
- May 26, 2026
- Duration seconds
- 2235
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/innovation-storytellers-3701797/episodes/259-how-peptides-are-innovating-longevity-planning/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/innovation-storytellers-3701797/259-how-peptides-are-innovating-longevity-planning.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
What happens when elite endurance training, wearable data, artificial intelligence, and peptide therapy collide? In this episode of the Innovation Storytellers Show, I sat down with Tony Medrano, CEO and co-founder of LongevityPlan.AI , to unpack how the future of longevity is being shaped by technology that once felt more science fiction than healthcare strategy. Tony's journey alone feels like a case study in reinvention. A former naval officer, Stanford entrepreneur, AI startup founder, and three-time Ironman triathlete, he has spent decades building companies around emerging technologies long before the market was ready for them. From helping shape the early mobile app ecosystem before smartphones even existed to working with organizations like NASA, the NFL, and Google on AI and molecular diagnostics, Tony has repeatedly found himself at the edge of major technology shifts. But this conversation quickly moved beyond startup stories and venture capital war stories. We explored how peptide therapies are being used to support recovery, performance optimization, injury repair, and preventative health, particularly as people search for ways to extend not just lifespan, but healthspan. Tony explained how LongevityPlan.AI combines wearable technology, biomarker analysis, AI-powered digital twins, and physician-guided peptide programs to create personalized health optimization plans. What made this discussion especially fascinating was the tension between innovation and evidence. Tony openly acknowledged that peptide therapies still sit in a space where anecdotal results, emerging science, and limited large-scale clinical trials coexist. That creates both excitement and skepticism. For some, this represents the future of preventative healthcare and human optimization. For…